Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06916000

Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of medicine, Ain Shams University

Abbasia, Cairo Governorate, 11517, Egypt

About this study

PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age group: 18 years and older.
  • ASA classification I to III.
  • BMI : 18-35 .
  • Gender: both sex

Exclusion criteria

  • Patient refusal.
  • Patients on long-term pain medications.
  • History of allergic reactions to local anesthetics
  • Patients who had mental illness or uncooperative patients.
  • BMI > 35 .
  • Patients having coagulopathies or on anticoagulant or antiplatelet therapy.
  • Severe cardiopulmonary disease
  • ASA IV or more
  • Diabetic or other neuropathies

Treatment and study plan

Pericapsular nerve group (PENG) block

Drug

As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.

All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points.

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Other

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Primary outcomes

  1. Pain score: pain assessment using a Numeric Rating System (NRS) immediately in the postoperative period.

    Time frame: 24 hours

    Pain score: pain intensity will be evaluated using a Numeric Rating System (NRS) immediately in the postoperative period, every 2 hours during the first 6 hours and then every 6 hours till 24 hours postoperatively. Scores ranging from 0 to 10, with 0 indicating the absence of pain and 10 indicating the worst possible pain.

Secondary outcomes

  1. Rescue analgesia timing and opioid consumption over 24 hours

    Time frame: 24 hours

    Time to first opioid demand and total opioid consumed by each patient individually over 24 hours.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of Ultrasound Guided Pericapsular Nerve Group (PENG) Block on Perioperative Pain Management in Patients Undergoing Hip Arthroplasty

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 8, 2025
Registry last updated
Apr 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.